Brian D. Jamieson

Anesthesiology

2700 Wayne Memorial Dr
Goldsboro, NC 27534

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial.

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial.

Journal: British journal of haematology

Published: February 23, 2026

Avatrombopag for treating children and adolescents with immune thrombocytopenia: a plain language summary.

Avatrombopag for treating children and adolescents with immune thrombocytopenia: a plain language summary.

Journal: Expert review of hematology

Published: December 18, 2025

Correction: A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia.

Correction: A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia.

Journal: International journal of hematology

Published: August 19, 2025

A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia.

A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia.

Journal: International journal of hematology

Published: January 06, 2025

Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA.

Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA.

Journal: Blood advances

Published: December 17, 2024

Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study.

Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study.

Journal: The Lancet. Haematology

Published: November 29, 2024

Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure.

Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure.

Journal: Medicine

Published: October 06, 2023

Plasma gastric biomarker evaluation with avatrombopag dosing in patients with chronic immune thrombocytopenia in phase 3 trials.

Plasma gastric biomarker evaluation with avatrombopag dosing in patients with chronic immune thrombocytopenia in phase 3 trials.

Journal: British journal of haematology

Published: March 07, 2023

A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP.

A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP.

Journal: British journal of haematology

Published: March 07, 2023

Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis.

Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis.

Journal: Therapeutic advances in gastroenterology

Published: February 09, 2022

Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.

Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: The Lancet. Haematology

Published: October 16, 2021

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.

Journal: British journal of haematology

Published: May 14, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026